San Francisco startup Structure Therapeutics can be focusing on an oral, once-everyday GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s anticipations in June each time a mid-phase study confirmed ordinary weight loss of all-around 6% and it strategies to start out An additional mid-stage trial to the top of the 12 months—that found